A Phase 2 Randomized, Double-Blind, Vehicle-Controlled, Dose-Ranging Study to Investigate the Efficacy and Safety of ME1111 in Patients With Mild to Moderate Onychomycosis
Phase of Trial: Phase II
Latest Information Update: 27 Mar 2017
Price : $35 *
At a glance
- Drugs ME 1111 (Primary)
- Indications Onychomycosis
- Focus Therapeutic Use
- Sponsors Meiji Seika Pharma
- 22 Mar 2017 Status changed from active, no longer recruiting to completed.
- 19 Oct 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
- 27 Aug 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.